Zirui Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zirui Zhou has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Benton Chuter
Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN 38163, USA
3 shared publications - Monica M. Jablonski
Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN 38163, USA
3 shared publications - Gideon Wall
College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA
2 shared publications - Min Young Kim
Department of Ophthalmology, Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, TN 38163, USA
2 shared publications - Noah Emmert
Department of Computer Science and Software Engineering, Miami University, Oxford, OH 45056, USA
2 shared publications - T. J. Hollingsworth
Department of Ophthalmology, Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, TN 38163, USA
2 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8681
Pregabalin and α2δ Subunit Modulation: A Systematic Review of Preclinical Evidence for Intraocular Pressure Regulation and Retinal Neuroprotection
Background: Glaucoma is a multifactorial optic neuropathy characterized by progressive retinal ganglion cell (RGC) loss, in which both intraocular pressure (IOP)-dependent and -independent mechanisms contribute to disease progression. Gabapentinoids target α2δ subunits of voltage-gated calcium channels (VGCCs), which regulate calcium-dependent processes relevant to both aqueous humor dynamics and retinal neuronal function. This systematic review evaluates heterogeneous evidence relevant to α2δ modulation of IOP regulation, retinal neuroprotection, and associated molecular and synaptic pathways. Methods: A systematic literature search was conducted across PubMed, Embase, Scopus, and Cochrane Library databases from inception. Studies investigating gabapentinoids or α2δ subunit modulation with outcomes related to IOP, RGC survival, or relevant molecular signaling were included. Risk of Bias (RoB) was assessed using the OHAT rating tool, and Certainty of Evidence (CoE) was rated on the GRADE four-level scale using initial confidence criteria from the OHAT approach. Due to heterogeneity in study design and outcomes, findings were synthesized narratively, with included studies divided and assessed separately within anterior segment pharmacology, anterior segment genetics, neuroprotection, and mechanistic bodies of evidence. Results: Of 1973 unique records screened, 11 studies met inclusion criteria, which were further subdivided into 15 experimental arms according to evidence type. Distinct evidence bodies were anterior segment pharmacology (5 study arms), anterior segment genetics (3 study arms), neuroprotection (4 study arms), and mechanistic (3 study arms). Across mouse and rabbit models of spontaneous ocular hypertension, topical pregabalin (PRG) consistently reduced IOP in a dose-dependent manner, with peak effects generally occurring 1.5–5 h after administration depending on strain and formulation. Plateaus in maximal IOP reduction were observed at 0.9% PRG solution in mice and 0.6–0.7% PRG microemulsion (ME) in rabbits. ME formulations of PRG consistently prolonged duration of action and increased cumulative exposure relative to non-ME PRG formulations. PRG ME achieved maximal IOP reduction comparable to that of 0.005% latanoprost solution while retaining their increased duration of action and cumulative exposure. Repeated once-daily PRG ME dosing maintained IOP-lowering responses over 21- and 60-day treatment periods. Genetic studies separately associated CACNA2D1/Cacna2d1 with IOP-related phenotypes and primary open-angle glaucoma susceptibility, providing target-level evidence. Preclinical posterior segment studies reported retinal structural preservation or improved RGC survival with PRG, while separate studies of GBP-L demonstrated RGC-survival effects associated with K-ATP channel activity rather than established α2δ modulation. Mechanistic studies separately identified thrombospondin-2 (TSP2)-α2δ1 signaling as a mediator of injury-associated synaptic remodeling, with pharmacologic disruption attenuating synaptic protein upregulation and improving axonal integrity. RoB varied across study arms and bodies of evidence. Anterior pharmacology included five Tier II study arms, anterior genetics included two Tier I arms and one Tier II arm, and all neuroprotection and mechanistic arms were Tier II. CoE was rated moderate for both anterior pharmacology and genetics, and low for both neuroprotection and mechanistic evidence. Conclusions: The available evidence is predominantly preclinical and heterogeneous. Moderate certainty within the defined anterior segment evidence body reflects consistency of the reported preclinical effect and does not establish clinical efficacy or independent reproducibility, as the topical PRG intervention literature is concentrated within a single investigative group. The neuroprotective and mechanistic findings remain hypothesis-generating and do not establish a unified mechanism or simultaneous IOP-lowering and neuroprotective action. Independent pharmacologic replication, validation in chronic glaucomatous neurodegeneration models, and long-term topical safety evaluation are prerequisites to discussions of clinical relevance.
- 6 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8681
Open AccessPregabalin and α2δ Subunit Modulation: A Systematic Review of Preclinical Evidence for Intraocular Pressure Regulation and Retinal Neuroprotection
Background: Glaucoma is a multifactorial optic neuropathy characterized by progressive retinal ganglion cell (RGC) loss, in which both intraocular pressure (IOP)-dependent and -independent mechanisms contribute to disease progression. Gabapentinoids target α2δ subunits of voltage-gated calcium channels (VGCCs), which regulate calcium-dependent processes relevant to both aqueous humor dynamics and retinal neuronal function. This systematic review evaluates heterogeneous evidence relevant to α2δ modulation of IOP regulation, retinal neuroprotection, and associated molecular and synaptic pathways. Methods: A systematic literature search was conducted across PubMed, Embase, Scopus, and Cochrane Library databases from inception. Studies investigating gabapentinoids or α2δ subunit modulation with outcomes related to IOP, RGC survival, or relevant molecular signaling were included. Risk of Bias (RoB) was assessed using the OHAT rating tool, and Certainty of Evidence (CoE) was rated on the GRADE four-level scale using initial confidence criteria from the OHAT approach. Due to heterogeneity in study design and outcomes, findings were synthesized narratively, with included studies divided and assessed separately within anterior segment pharmacology, anterior segment genetics, neuroprotection, and mechanistic bodies of evidence. Results: Of 1973 unique records screened, 11 studies met inclusion criteria, which were further subdivided into 15 experimental arms according to evidence type. Distinct evidence bodies were anterior segment pharmacology (5 study arms), anterior segment genetics (3 study arms), neuroprotection (4 study arms), and mechanistic (3 study arms). Across mouse and rabbit models of spontaneous ocular hypertension, topical pregabalin (PRG) consistently reduced IOP in a dose-dependent manner, with peak effects generally occurring 1.5–5 h after administration depending on strain and formulation. Plateaus in maximal IOP reduction were observed at 0.9% PRG solution in mice and 0.6–0.7% PRG microemulsion (ME) in rabbits. ME formulations of PRG consistently prolonged duration of action and increased cumulative exposure relative to non-ME PRG formulations. PRG ME achieved maximal IOP reduction comparable to that of 0.005% latanoprost solution while retaining their increased duration of action and cumulative exposure. Repeated once-daily PRG ME dosing maintained IOP-lowering responses over 21- and 60-day treatment periods. Genetic studies separately associated CACNA2D1/Cacna2d1 with IOP-related phenotypes and primary open-angle glaucoma susceptibility, providing target-level evidence. Preclinical posterior segment studies reported retinal structural preservation or improved RGC survival with PRG, while separate studies of GBP-L demonstrated RGC-survival effects associated with K-ATP channel activity rather than established α2δ modulation. Mechanistic studies separately identified thrombospondin-2 (TSP2)-α2δ1 signaling as a mediator of injury-associated synaptic remodeling, with pharmacologic disruption attenuating synaptic protein upregulation and improving axonal integrity. RoB varied across study arms and bodies of evidence. Anterior pharmacology included five Tier II study arms, anterior genetics included two Tier I arms and one Tier II arm, and all neuroprotection and mechanistic arms were Tier II. CoE was rated moderate for both anterior pharmacology and genetics, and low for both neuroprotection and mechanistic evidence. Conclusions: The available evidence is predominantly preclinical and heterogeneous. Moderate certainty within the defined anterior segment evidence body reflects consistency of the reported preclinical effect and does not establish clinical efficacy or independent reproducibility, as the topical PRG intervention literature is concentrated within a single investigative group. The neuroprotective and mechanistic findings remain hypothesis-generating and do not establish a unified mechanism or simultaneous IOP-lowering and neuroprotective action. Independent pharmacologic replication, validation in chronic glaucomatous neurodegeneration models, and long-term topical safety evaluation are prerequisites to discussions of clinical relevance.
- Open Access
A Systematic Review and Independent Benchmarking of Automated Nerve Morphometry Methods
Objective: To systematically review automated nerve morphometry tools and independently benchmark their performance on independent optic nerve datasets. Design: Systematic review and comparative benchmarking study. Controls: Benchmarking was performed using paraphenylenediamine-stained mouse (n = 85) and rat (n = 44) optic nerve images with manually annotated axon counts as ground truth. Methods: Published studies describing automated or semi-automated neural tissue morphometry tools were identified through systematic searches of PubMed, Embase, and Scopus through January 2026 following PRISMA guidelines. Data extraction covered 70 fields across tool capabilities, imaging modality, species, automation level, and validation approach. Eighteen eligible tools (8 deep learning [DL], 10 classical computer vision [CV]) were benchmarked on both mouse and rat independent datasets. Main Outcome Measures: Performance was assessed by mean absolute percentage error (MAPE), Pearson correlation, and median predicted-to-ground-truth ratio. Tools were ranked per image and compared using Friedman tests with Nemenyi post-hoc analysis. Results: Seventy-one studies met inclusion criteria, spanning from 1999 to 2026. Deep learning methods represented 38% (27/71) of studies, increasing from 0% before 2017 to over 55% of publications after 2020. Axon counting was the most common output (73%, 52/71), while only 35% (25/71) reported g-ratio. Among benchmarked tools, Marina (CV, 2010) achieved the lowest average MAPE (32.9%). The top five tools (MAPE ranging from 32.9 to 44.8%) included both CV and DL methods and were statistically indistinguishable by Friedman-Nemenyi analysis (p > 0.05). Performance varied substantially across datasets: AxonJ (CV) achieved the second best MAPE on rat images (27.7%) but the worst on mouse images (438.6%). Conclusions: No single tool demonstrated consistently superior performance across both datasets. Classical and deep learning approaches achieved comparable accuracy for axon counting. Tool selection should be guided by target species, tissue preparation protocol, and desired morphometric outputs. This systematic review and independent benchmarking study provide an evidence base for tool selection in optic nerve research.
Open AccessA Systematic Review and Independent Benchmarking of Automated Nerve Morphometry Methods
Objective: To systematically review automated nerve morphometry tools and independently benchmark their performance on independent optic nerve datasets. Design: Systematic review and comparative benchmarking study. Controls: Benchmarking was performed using paraphenylenediamine-stained mouse (n = 85) and rat (n = 44) optic nerve images with manually annotated axon counts as ground truth. Methods: Published studies describing automated or semi-automated neural tissue morphometry tools were identified through systematic searches of PubMed, Embase, and Scopus through January 2026 following PRISMA guidelines. Data extraction covered 70 fields across tool capabilities, imaging modality, species, automation level, and validation approach. Eighteen eligible tools (8 deep learning [DL], 10 classical computer vision [CV]) were benchmarked on both mouse and rat independent datasets. Main Outcome Measures: Performance was assessed by mean absolute percentage error (MAPE), Pearson correlation, and median predicted-to-ground-truth ratio. Tools were ranked per image and compared using Friedman tests with Nemenyi post-hoc analysis. Results: Seventy-one studies met inclusion criteria, spanning from 1999 to 2026. Deep learning methods represented 38% (27/71) of studies, increasing from 0% before 2017 to over 55% of publications after 2020. Axon counting was the most common output (73%, 52/71), while only 35% (25/71) reported g-ratio. Among benchmarked tools, Marina (CV, 2010) achieved the lowest average MAPE (32.9%). The top five tools (MAPE ranging from 32.9 to 44.8%) included both CV and DL methods and were statistically indistinguishable by Friedman-Nemenyi analysis (p > 0.05). Performance varied substantially across datasets: AxonJ (CV) achieved the second best MAPE on rat images (27.7%) but the worst on mouse images (438.6%). Conclusions: No single tool demonstrated consistently superior performance across both datasets. Classical and deep learning approaches achieved comparable accuracy for axon counting. Tool selection should be guided by target species, tissue preparation protocol, and desired morphometric outputs. This systematic review and independent benchmarking study provide an evidence base for tool selection in optic nerve research.
- Open Access
- 30 May 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (6) , 647
Comparison of Deep Learning Tools for Optic Nerve Axon Quantification Finds Limited Generalizability Upon Independent Validation
Machine learning approaches for automated quantification of optic nerve histology have emerged as tools for the objective assessment of axonal injury in experimental glaucoma models. However, their generalizability to independent datasets remains unclear. Guided by a scoping review following PRISMA-ScR guidelines, this study evaluated the performance of publicly available models on novel datasets. PubMed, EMBASE, Scopus, and Cochrane CENTRAL were searched (2000–2025). Two reviewers screened studies and extracted model characteristics and performance metrics. Three models (AxoNet, AxonDeepSeg, and AxoNet 2.0) were independently validated on a rat optic nerve dataset (44 images; 6941 axons) and a mouse optic nerve dataset (74 full cross-sections). From 2036 records, four manuscripts describing three deep learning models met the inclusion criteria, with reported correlation coefficients of 0.959–0.99 between model predictions and reference counts. On the rat dataset, the performance correlation declined (r = 0.831–0.907), precision remained high (>0.94), but recall was low (0.18–0.27), with Dice coefficients of 0.29–0.40. On the mouse dataset, correlations decreased further (r = 0.57–0.74) and model rankings differed, reflecting the domain shift and scale-dependent effects. These findings demonstrate strong within-study performance but reduced generalizability to independent datasets, highlighting the need for standardized validation datasets and multi-center testing.
- 30 May 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (6) , 647
Open AccessComparison of Deep Learning Tools for Optic Nerve Axon Quantification Finds Limited Generalizability Upon Independent Validation
Machine learning approaches for automated quantification of optic nerve histology have emerged as tools for the objective assessment of axonal injury in experimental glaucoma models. However, their generalizability to independent datasets remains unclear. Guided by a scoping review following PRISMA-ScR guidelines, this study evaluated the performance of publicly available models on novel datasets. PubMed, EMBASE, Scopus, and Cochrane CENTRAL were searched (2000–2025). Two reviewers screened studies and extracted model characteristics and performance metrics. Three models (AxoNet, AxonDeepSeg, and AxoNet 2.0) were independently validated on a rat optic nerve dataset (44 images; 6941 axons) and a mouse optic nerve dataset (74 full cross-sections). From 2036 records, four manuscripts describing three deep learning models met the inclusion criteria, with reported correlation coefficients of 0.959–0.99 between model predictions and reference counts. On the rat dataset, the performance correlation declined (r = 0.831–0.907), precision remained high (>0.94), but recall was low (0.18–0.27), with Dice coefficients of 0.29–0.40. On the mouse dataset, correlations decreased further (r = 0.57–0.74) and model rankings differed, reflecting the domain shift and scale-dependent effects. These findings demonstrate strong within-study performance but reduced generalizability to independent datasets, highlighting the need for standardized validation datasets and multi-center testing.
- Open Access
- 1 February 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (7)
The D84G mutation in STIM1 causes nuclear envelope dysfunction and myopathy in mice
Stromal interaction molecule 1 (STIM1) is a Ca 2+ sensor located in the sarcoplasmic reticulum (SR) of skeletal muscle, where it is best known for its role in store-operated Ca 2+ entry (SOCE). Genetic syndromes resulting from STIM1 mutations are recognized as a cause of muscle weakness and atrophy. Here, we focused on a gain-of-function mutation that occurs in humans and mice (STIM1 +/D84G mice), in which muscles exhibited constitutive SOCE. Unexpectedly, this constitutive SOCE did not affect global Ca 2+ transients, SR Ca 2+ content, or excitation-contraction coupling (ECC) and was therefore unlikely to underlie the reduced muscle mass and weakness observed in these mice. Instead, we demonstrate that the presence of D84G STIM1 in the nuclear envelope of STIM1 +/D84G muscle disrupted nuclear-cytosolic coupling, causing severe derangement in nuclear architecture, DNA damage, and altered lamina A–associated gene expression. Functionally, we found that D84G STIM1 reduced the transfer of Ca 2+ from the cytosol to the nucleus in myoblasts, resulting in a reduction of [Ca 2+ ] N . Taken together, we propose a novel role for STIM1 in the nuclear envelope that links Ca 2+ signaling to nuclear stability in skeletal muscle.
- 1 February 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (7)
Open AccessThe D84G mutation in STIM1 causes nuclear envelope dysfunction and myopathy in mice
Stromal interaction molecule 1 (STIM1) is a Ca 2+ sensor located in the sarcoplasmic reticulum (SR) of skeletal muscle, where it is best known for its role in store-operated Ca 2+ entry (SOCE). Genetic syndromes resulting from STIM1 mutations are recognized as a cause of muscle weakness and atrophy. Here, we focused on a gain-of-function mutation that occurs in humans and mice (STIM1 +/D84G mice), in which muscles exhibited constitutive SOCE. Unexpectedly, this constitutive SOCE did not affect global Ca 2+ transients, SR Ca 2+ content, or excitation-contraction coupling (ECC) and was therefore unlikely to underlie the reduced muscle mass and weakness observed in these mice. Instead, we demonstrate that the presence of D84G STIM1 in the nuclear envelope of STIM1 +/D84G muscle disrupted nuclear-cytosolic coupling, causing severe derangement in nuclear architecture, DNA damage, and altered lamina A–associated gene expression. Functionally, we found that D84G STIM1 reduced the transfer of Ca 2+ from the cytosol to the nucleus in myoblasts, resulting in a reduction of [Ca 2+ ] N . Taken together, we propose a novel role for STIM1 in the nuclear envelope that links Ca 2+ signaling to nuclear stability in skeletal muscle.